Glenview Trust co Sells 14,283 Shares of Merck & Co., Inc. (NYSE:MRK)

Glenview Trust co lessened its stake in shares of Merck & Co., Inc. (NYSE:MRKFree Report) by 4.0% in the fourth quarter, Holdings Channel reports. The institutional investor owned 341,990 shares of the company’s stock after selling 14,283 shares during the period. Glenview Trust co’s holdings in Merck & Co., Inc. were worth $34,021,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Midwest Capital Advisors LLC bought a new position in shares of Merck & Co., Inc. during the fourth quarter valued at $26,000. Financial Life Planners purchased a new stake in Merck & Co., Inc. during the 4th quarter valued at about $28,000. Noble Wealth Management PBC purchased a new stake in Merck & Co., Inc. during the 4th quarter valued at about $28,000. Halbert Hargrove Global Advisors LLC bought a new stake in Merck & Co., Inc. during the 4th quarter valued at about $28,000. Finally, Promus Capital LLC purchased a new position in Merck & Co., Inc. in the fourth quarter worth about $30,000. Hedge funds and other institutional investors own 76.07% of the company’s stock.

Insider Buying and Selling at Merck & Co., Inc.

In other Merck & Co., Inc. news, Director Inge G. Thulin purchased 2,833 shares of the business’s stock in a transaction on Thursday, February 6th. The stock was acquired at an average price of $88.25 per share, for a total transaction of $250,012.25. Following the purchase, the director now owns 2,933 shares of the company’s stock, valued at approximately $258,837.25. This represents a 2,833.00 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Cristal N. Downing sold 2,361 shares of the business’s stock in a transaction dated Thursday, February 6th. The shares were sold at an average price of $88.76, for a total value of $209,562.36. Following the completion of the transaction, the insider now owns 7,085 shares in the company, valued at $628,864.60. The trade was a 24.99 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.09% of the company’s stock.

Merck & Co., Inc. Trading Up 0.0 %

Shares of MRK stock opened at $94.72 on Friday. The company has a debt-to-equity ratio of 0.79, a current ratio of 1.36 and a quick ratio of 1.15. The company has a market cap of $239.27 billion, a price-to-earnings ratio of 14.07, a PEG ratio of 0.77 and a beta of 0.35. Merck & Co., Inc. has a 1 year low of $81.04 and a 1 year high of $134.63. The firm has a fifty day moving average price of $93.57 and a 200-day moving average price of $101.88.

Merck & Co., Inc. (NYSE:MRKGet Free Report) last released its quarterly earnings results on Tuesday, February 4th. The company reported $1.72 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.85 by ($0.13). The company had revenue of $15.62 billion for the quarter, compared to the consensus estimate of $15.51 billion. Merck & Co., Inc. had a net margin of 26.67% and a return on equity of 45.35%. The business’s revenue for the quarter was up 6.8% on a year-over-year basis. During the same period in the prior year, the firm posted $0.03 EPS. As a group, equities analysts predict that Merck & Co., Inc. will post 9.01 earnings per share for the current year.

Merck & Co., Inc. declared that its board has approved a share buyback program on Tuesday, January 28th that allows the company to repurchase $10.00 billion in outstanding shares. This repurchase authorization allows the company to repurchase up to 4.1% of its shares through open market purchases. Shares repurchase programs are generally an indication that the company’s management believes its shares are undervalued.

Merck & Co., Inc. Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, April 7th. Shareholders of record on Monday, March 17th will be paid a dividend of $0.81 per share. This represents a $3.24 dividend on an annualized basis and a yield of 3.42%. The ex-dividend date is Monday, March 17th. Merck & Co., Inc.’s payout ratio is 48.14%.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on the stock. TD Securities cut shares of Merck & Co., Inc. from a “buy” rating to a “hold” rating and cut their price target for the company from $121.00 to $100.00 in a report on Monday, February 10th. Citigroup reduced their target price on Merck & Co., Inc. from $125.00 to $115.00 and set a “buy” rating for the company in a report on Wednesday, February 5th. Deutsche Bank Aktiengesellschaft cut Merck & Co., Inc. from a “buy” rating to a “hold” rating and decreased their price target for the stock from $128.00 to $105.00 in a research note on Tuesday, February 18th. BMO Capital Markets dropped their price objective on Merck & Co., Inc. from $105.00 to $96.00 and set a “market perform” rating on the stock in a research report on Wednesday, February 5th. Finally, Truist Financial reissued a “hold” rating and issued a $110.00 target price (down previously from $130.00) on shares of Merck & Co., Inc. in a research report on Wednesday, January 8th. Eleven investment analysts have rated the stock with a hold rating, nine have assigned a buy rating and three have issued a strong buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $117.12.

View Our Latest Stock Analysis on MRK

About Merck & Co., Inc.

(Free Report)

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.

Featured Articles

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRKFree Report).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.